This page is for HCPs* and ORDMs** in Great Britain. Information on this page is aligned to the Great Britain Summary of Product Characteristics. 
Information about adverse event reporting can be found towards the bottom of the page

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Menu

Close

AboutmRNA TechnologyMechanism of ActionDosing & AdministrationComirnaty Omicron XBB.1.5Dosing & Administration StorageComirnaty Omicron XBB.1.5 30mcg 12 years + (Grey cap)How to OrderComirnaty Omicron XBB.1.5 Supply for Great BritainResourcesMaterialsVideosEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Dosing: 12 yrs +COMIRNATY Omicron XBB.1.5 helps protect against COVID-19 with a 30mcg dose1
  • COMIRNATY Omicron XBB.1.5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 12 years of age and over. The use of this vaccine should be in accordance with official recommendations and at least 3 months since the last prior COVID-19 Vaccine1.

  • Concomitant administration of COMIRNATY Omicron XBB.1.5 with other vaccines has not been studied.

Scroll left to view table
Dosing: 12 yrs +Dosing: 12 yrs +
Dosage 30 mcg of raxtozinameran
Injection Volume per Dose 0.3 mL
Dilution No dilution required
Vial size 2ml
Doses per Vial 1 dose per vial
Administration: 12 yrs +
  • COMIRNATY Omicron XBB.1.5 30 micrograms/dose is administered intramuscularly into the deltoid muscle of the upper arm as a single dose of 0.3 mL for individuals 12 years of age and older regardless of prior COVID-19 vaccination status1.
  • For individuals who have previously been vaccinated with a COVID-19 vaccine, COMIRNATY Omicron XBB.1.5 should be administered at least 3 months after the most recent dose of a COVID-19 vaccine1.
  • Watch the animation below to learn more about the preparation and administration of COMIRNATY Omicron XBB.1.5 30mcg single dose vials:
Reference:COMIRNATY Omicron XBB.1.5 Single Dose Vial Summary of Product Characteristics
Additional Information

For more details about the other presentations of COMIRNATY Omicron XBB.1.5, for use in the National Immunisation Programme, please refer to the Summary of Product Characteristics or visit the COMIRNATY Education site.


https://www.comirnatyeducation.co.uk
PP-CMR-GBR-0506. February 2024

Adverse Event Reporting

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. 

Healthcare professionals are asked to report any suspected adverse reactions via a Yellow card. Reporting forms and information can be found at https://coronavirus-yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store and include the batch/Lot number if available.

Alternatively, adverse events of concern in association with COMIRNATY can be reported to Pfizer Medical Information on 01304 616161 or via www.pfizersafetyreporting.com.

Please do not report the same adverse event(s) to both systems as all reports will be shared between Pfizer and MHRA (in an anonymised form) and dual reporting will create unnecessary duplicates.

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

Marketing Authorisation
Holder: BioNTech
Manufacturing GmbH

COMIRNATY, COMIRNATY Omicron XBB.1.5, are based on BioNTech proprietary mRNA technology, developed by both BioNTech and Pfizer.


The product information provided in this site is intended only for Healthcare Professionals and Other Relevant Decision Makers resident in the United Kingdom. 


This website is brought to you by Pfizer Limited, a company registered in England and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent CT13 9NJ.

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-CMR-GBR-0512. January 2024
 

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​